Press Releases

Company Joins the Decentralized Trials & Research Alliance

Clinical Ink, a global clinical trial technology company, today announced five years of providing clients with decentralized and hybrid trial solutions. To demonstrate our continued commitment to industry leadership and the movement toward more patient-centric clinical trials, Clinical Ink has joined the Decentralized Trials & Research Alliance (DTRA), which enables collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. 

Clinical Ink has long been a pioneer of solutions that support decentralized, real-time clinical trial data collection for sites and patients. This year marks the five-year anniversary of two Ebola vaccine studies in which Clinical Ink remotely supported 5,000 patients with rapid enrollment and WHO-mandated timelines. Overall, Clinical Ink has completed over 300 studies in all phases (I–IV) in 60 countries/70 languages and executed 50+ BYOD studies. Clinical Ink is far and away the most experienced eSource provider in the industry. 

“Building on our extensive experience in decentralized trials, we transitioned numerous studies that were site-based to home-based during the pandemic,” said Ed Seguine, Clinical Ink CEO. “Our direct data capture (DDC) technology is the gold standard for COVID-19 studies because it permits data access and remote monitoring in real time. Our BYOD ePRO experience for patients helps improve compliance and simplify patient participation in clinical trials. Clinical Ink is committed to supporting meaningful improvements in clinical trials (#NoGoingBack). In that spirit, we are proud to join the DTRA as we work toward the technological changes our industry and its patients require.” 

Clinical Ink’s Lunexis^TM platform enables remote participation while providing a full suite of mixed modalities: a single platform that allows patients and sites to switch back and forth among phone, tablet, or web, at virtual or physical sites, as desired. Lunexis supports BYOD, eConsent, telehealth/medicine, and more, bringing all data together from remote environments. 

“Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives — and by taking part in the DTRA, Clinical Ink is demonstrating its leadership to drive change,” said Craig Lipset, DTRA co-convener and clinical innovation advisor. “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, regulators, technology leaders, and patient communities, we can remove remaining barriers to adoption and impact patients today.” 

About Clinical Ink
Clinical Ink, a global clinical technology company, offers data certainty from source to submission. Our Lunexis™ eSource clinical technology and configurable direct data capture, eCOA, ePRO, and eConsent modules — a suite of solutions for capturing and integrating electronic data from sites, clinicians, and patients at its source — naturally enhance your clinical trial workflow by reducing manual labor, providing anytime, anywhere data access, and saving resources as your trials progress.